Drug Trial Radar · NCT06526793
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Nov 27, 2024
Primary completion
Apr 21, 2028
Study completion Oct 21, 2032
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.
Conditions
- B-cell Non-Hodgkin Lymphoma
- Follicular Lymphoma (FL)
- Large B-Cell Lymphoma (LBCL)
Interventions
SurovatamigDrug
Investigational Product administered via intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR) (central review)Time frame: Module 1: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to approximately 24 months. Module 2: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to approximately 12 months.
Locations
94 sites in 16 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona · Withdrawn
Research Site
Duarte, California · Recruiting
Research Site
Jacksonville, Florida · Withdrawn
Research Site
Tampa, Florida · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Iowa City, Iowa · Withdrawn
Research Site
Waukee, Iowa · Recruiting
Research Site
Overland Park, Kansas · Withdrawn
Research Site
Rochester, Minnesota · Recruiting
Research Site
St Louis, Missouri · Withdrawn
Research Site
New Brunswick, New Jersey · Withdrawn
Research Site
New York, New York · Recruiting
Research Site
Charlotte, North Carolina · Recruiting
Research Site
Columbus, Ohio · Recruiting
Research Site
Portland, Oregon · Recruiting
Research Site
Philadelphia, Pennsylvania · Recruiting
Research Site
Pittsburgh, Pennsylvania · Recruiting
Research Site
Pittsburgh, Pennsylvania · Withdrawn
Research Site
Nashville, Tennessee · Recruiting
Research Site
Austin, Texas · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
San Antonio, Texas · Recruiting
Research Site
Milwaukee, Wisconsin · Recruiting
Research Site
Heidelberg, Australia · Recruiting
Research Site
Kogarah, Australia · Recruiting
Research Site
Macquarie University, Australia · Recruiting
Research Site
Nedlands, Australia · Recruiting
Research Site
Porto Alegre, Brazil · Withdrawn
Research Site
São Paulo, Brazil · Active not recruiting
Research Site
São Paulo, Brazil · Active not recruiting
Research Site
Barrie, Ontario, Canada · Withdrawn
Research Site
Brampton, Ontario, Canada · Recruiting
Research Site
Ottawa, Ontario, Canada · Recruiting
Research Site
Toronto, Ontario, Canada · Recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Nanchang, China · Recruiting
Research Site
Nanjing, China · Recruiting
Research Site
Nantong, China · Recruiting
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.